Earnings Preview: Intelia Therapeutics, Inc. (NTLA) Q4 earnings are expected to decline

Intelia Therapeutics, Inc. announced its results for the quarter ending December 2019. A powerful factor affecting its near-stock price which you can check at https://www.webull.com/quote/nasdaq-ntla is how real results compare with its valuations.

If these key numbers are better than expectations, the earnings report will help the stock go higher. On the other hand, if they miss, the stock may move less.

Although instantaneous price change and the stability of future earnings expectations largely depend on the management’s discussion of business conditions in the earnings call, it is worth dealing with the probability of a positive EPS surprise.

Zacks consensus rating

The company is expecting a quarterly loss of $ 0.54 per share in its upcoming report, which represents a year-over-year change of -25.6%.

Revenue is expected to be $ 9.55 million, up 21.2% from the prior-year quarter.

Estimate the trend of corrections

Whisper of revenue

Revised estimates before a company’s earnings release provide clues to the business conditions for the period in which its results are released. Our proprietary surprise forecasting model – Zacks Revenue ESP (Expected Surprise Prediction) – has this insight at its core.

Zacks ’consensus estimate of Zacks Revenue ESP for the quarter is compared to Zacks’ consensus estimate; The most accurate estimate is the most recent version of the Zacks Consensus EPS estimate. The idea here is that analysts have been revising their estimates even before the earnings release, which is more accurate than previously predicted by them and others.

Therefore, a positive or negative return ESP reading theoretically represents a deviation from the actual return. However, the predictive power of the model is only significant for positive ESP measurements.

Positive Earnings ESP is a strong predictor of an earnings beat, especially if the Jags rank # 1 (strong buy), 2 (buy) or 3 (hold). Our research shows that derivatives with this combination generate a positive surprise almost 70% of the time, and a solid jack’s rating increases the forecasting power of earnings ESP.

Note that negative earnings do not imply an ESP reading revenue loss. Our research shows that it is difficult to predict earnings with negative earnings ESP metrics and/or any confidence for stocks that have a Zacks rating of 4 (Sell) or 5 (strong sell).

Intelia Therapeutics, Inc.

Intelia Therapeutics, Inc. The most accurate estimate is similar to the Jack consensus estimate, which suggests that there are no recent analyst views that differ from those considered for obtaining consensus estimates. As a result, 0% earnings are expected to remain in the ESP.

Some investors rely on dividends for growing their wealth, and if you’re one of those dividend sleuths, you might be intrigued to know that Big Lots, Inc. (NYSE:BIG https://www.webull.com/quote/nyse-big) is about to go ex-dividend in just 4 days. You can purchase shares before the 19th of March in order to receive the dividend, which the company will pay on the 3rd of April.

Big Lots’s upcoming dividend is US$0.30 a share, following on from the last 12 months, when the company distributed a total of US$1.20 per share to shareholders. Calculating the last year’s worth of payments shows that Big Lots has a trailing yield of 8.5% on the current share price of $14.11. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That’s why we should always check whether the dividend payments appear sustainable, and if the company is growing.